Patogenia, diagnóstico y tratamiento | 10 NOV 19

Espondiloartritis

Grupo heterogéneo de enfermedades caracterizado por la inflamación crónica de las entesis y otras estructuras anatómicas, que causa sacroileitis, entesitis y artritis periférica
Autor/a: Pilar S. del Río-Martínez EMJ. 2016;1[3]:96-102
INDICE:  1. Página 1 | 2. Página 2
Página 2

 

REFERENCIAS

1. Khan MA. Update on Spondyloarthropathies. Ann Intern Med. 2002; 136(12):896-907.

2. Rudwaleit M et al. The development of Assessment of SpondyloArthritis. International Society classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009; 68(6):770-6.

3. Rudwaleit M et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis. 2009; 68(6):777-83.

4. Rudwaleit M et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011; 70(1):25-31.

5. Stolwijk C et al. The global prevalence of spondyloarthritis: A systematic review and meta-regression analysis. Arthritis Care Res (Hoboken). 2015. [Epub ahead of print]

6. Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev. 2010; 233(1):162-80

7. Brown MA et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997; 40(10):1823.

8. van der Heijde D et al.; Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009; 68:1811-8.

9. Brown MA et al. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2000; 59(11):883-6.

10. Reveille JD. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 2015; 34:1009-18.

11. Ben Dror L et al. The HLA-B*2705 peptidome. Arthritis Rheum. 2010; 62: 420-9.

12. López de Castro JA. The HLA-B27 peptidome: building on the cornerstone. Arthritis Rheum. 2010; 62(2):316-9.

13. Sorrentino R et al. HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity. Mol Immunol. 2014; 57(1):22-7.

14. Castro-Santos P et al. [Genetics of ankylosing spondylitis]. Rev Med Chil. 2014; 142:1165-73.

15. Yamaguchi A et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum. 1995; 38(11):1672-7.

16. Giovannini L et al. One year in review 2015: Spondyloarthritis. Clin Exp Rheumatol. 2015; 33:769-78.

17. Benjamin M, McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol. 2009; 649:57-70.

18. Maksymowych WP et al. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013; 72(1):23-8.

19. Jacques P, McGonagle D. The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol. 2014; 28:703-10.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024